New Guidelines Issued for Alzheimer’s Disease Diagnosis and Detection

The Haute Autorité de Santé (HAS) has updated its recommendations for the detection and diagnosis of Alzheimer’s disease to facilitate earlier identification of the condition. These guidelines emphasize a structured screening process led by primary care physicians and the integration of biological markers to confirm the presence of the disease, according to reporting by Egora.

The revised framework aims to reduce the time between the appearance of the first symptoms and a formal diagnosis. By standardizing the “repérage” or detection phase, health authorities intend to ensure that patients are referred to specialized memory centers more efficiently.

How is the early detection process structured?

Early detection begins with the primary care physician, who is tasked with identifying cognitive warning signs during routine consultations. According to the HAS guidelines, physicians should prioritize the identification of short-term memory loss and changes in executive function that interfere with daily living.

The recommendations specify the use of standardized cognitive screening tools to objectively measure impairment. These tools allow general practitioners to distinguish between normal age-related cognitive decline and potential pathological impairment before referring the patient to a specialist.

The screening process focuses on several key indicators:

• Recent memory deficits, specifically the inability to retain new information.
• Disorientation in time or space.
• Difficulty performing complex tasks that were previously routine.
• Changes in mood or personality, such as increased apathy or irritability.

What role do biomarkers play in the new diagnostic guidelines?

The updated guidelines move away from a “diagnosis by exclusion,” where Alzheimer’s was identified only after other causes were ruled out. Instead, the HAS now supports the strategic use of biomarkers to provide biological evidence of the disease, according to the reporting.

Biomarkers allow clinicians to detect the accumulation of amyloid-beta and tau proteins in the brain, which are the hallmarks of Alzheimer’s pathology. These markers can be identified through two primary methods: cerebrospinal fluid (CSF) analysis via lumbar puncture or Positron Emission Tomography (PET) scans.

The use of these tools is not recommended for every patient but is reserved for cases where the clinical diagnosis remains uncertain or where the patient’s profile suggests an atypical presentation of the disease.

Why does earlier diagnosis change patient management?

Earlier diagnosis allows for the implementation of non-pharmacological interventions and the management of comorbidities that can exacerbate cognitive decline. According to the HAS, providing a clear diagnosis early in the disease progression helps patients and families plan for future care and legal arrangements.

The shift toward biological confirmation also aligns French practice with international standards, such as those set by the National Institute on Aging and the Alzheimer’s Association (NIA-AA). This alignment is critical as new disease-modifying therapies, including monoclonal antibodies, specifically target the amyloid plaques that biomarkers detect.

The guidelines contrast the previous clinical-only approach with the current biological approach. While clinical observation remains the primary entry point, the addition of biomarkers reduces the rate of misdiagnosis and allows for a more precise classification of the type of dementia the patient is experiencing.

What are the limitations of the new recommendations?

The HAS acknowledges that the widespread adoption of biomarker testing depends on the availability of specialized equipment and trained personnel. Not all regions have equal access to PET scan facilities or the specialized neurology clinics required to perform and interpret CSF analyses.

Furthermore, the guidelines emphasize that a biological marker does not always equate to immediate clinical symptoms. The presence of amyloid plaques in an asymptomatic individual does not automatically result in a diagnosis of Alzheimer’s dementia, requiring clinicians to maintain a balance between biological data and observed cognitive impairment.